96
EligibleNCT05821439· 2m ago
Osimertinib + Savolitinib in EGFR-Mutant Advanced NSCLC
Phase IINSCLC · EGFR+Boston, MA · 4 mi
- EGFR exon 19 deletion
- Stage IIIB–IV disease
- ECOG 0–1
- Adequate renal function
Active matches
24+3 today
Avg. match score
85%+2.1%
Screening now
62 pending
Sites in network
1128 states
Patient profile
ME
Marcus Ellery
MRN-4820-117
58 yrsMaleStage IIIBECOG 1
Primary diagnosis
Non-small cell lung cancer
Biomarkers & labs
- EGFR
- Exon 19 del
- PD-L1 TPS
- 45%
- ALK
- Negative
- Creatinine
- 1.6 mg/dL
- Hemoglobin
- 10.9 g/dL
- ANC
- 3.1 K/µL
Medications
- Osimertinib 80mg
- Lisinopril 10mg
- Atorvastatin 20mg
Allergies
- Penicillin
- Contrast dye
Matched clinical trials
Live4 trials ranked by eligibility fit
88
Needs reviewNCT06017492· 9m ago
Novel KRAS G12C Inhibitor With Pembrolizumab Combination
Phase I/IINSCLC · PD-L1 ≥ 1%Cambridge, MA · 7 mi
- PD-L1 TPS ≥ 1%
- No prior immunotherapy
- Measurable disease (RECIST 1.1)
- KRAS G12C mutation
82
ScreeningNCT05733208· 21m ago
Adaptive Radiotherapy Plus Durvalumab Consolidation
Phase IIIStage III NSCLCProvidence, RI · 41 mi
- Unresectable Stage III
- Completed chemoradiation
- ECOG 0–1
- No autoimmune disease
74
ScreeningNCT06204591· 34m ago
Antibody-Drug Conjugate for HER2-Altered Solid Tumors
Phase IIHER2 · BasketWorcester, MA · 48 mi
- HER2 alteration confirmed
- Progression on prior therapy
- Adequate cardiac function
- ECOG 0–2
Matching Agent
Grounded on this patient's chart
I reviewed Marcus Ellery's chart and cross-referenced 112 active sites. The strongest fit is the EGFR-mutant NSCLC study (96%). Ask me anything about eligibility, criteria gaps, or next steps.